PharmaTimes September 23, 2021
Novartis has announced its acquisition of Arctos Medical as it looks to expand its gene therapy pipeline further, adding a pre-clinical optogenetics-based AAV gene therapy programme to its portfolio.
As part of the takeover, Novartis will also add Arctos’ proprietary technology to its ophthalmology portfolio – this technology is a potential method for treating inherited retinal dystrophies (IRDs) and other diseases that involve photoreceptor loss.
While existing gene therapy treatments aim to correct a specific gene, Novartis said in a statement that Arctos’ technology is not limited to one gene, and can potentially address many forms of IRDs, regardless of the underlying mutation.
Arctos’ optogene is delivered to specific retinal cells using...
Today's Sponsors
Today's Sponsor